Source: Moneycontrol

Profectus Biosciences: Aurobindo Pharma share price up 2% on assets acquisition of US firm

The assets acquisition is for upfront cash consideration of $11.29 million.

Read full article »
Profectus Biosciences's Competitors | Profectus Biosciences's News | Profectus Biosciences's Financials
Stay up-to-date with the latest news on Profectus Biosciences
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
Jeffrey N. Meshulam's photo - President of Profectus Biosciences

President

Jeffrey N. Meshulam

CEO Approval Rating

87/100

Read more
Stay up-to-date with the latest news on Profectus Biosciences